Name change from Leadartis and launch of new website

Trimerbody Pharma, a clinical stage biopharmaceutical company developing proprietary therapeutic antibodies called Trimerbodies against cancer, announces that it has changed its name from Leadartis with immediate effect. The Company has launched a new corporate website, www.trimerbodypharma.com , and associated rebranding.

The Trimerbody immunotherapeutic platform is built around a unique trimeric configuration of bispecific antibodies, which enables simultaneous engagement of two distinct targets with enhanced spatial flexibility and stability. This structural design not only improves binding avidity but also supports more effective immune synapse formation, making it particularly well-suited for next-generation T cell redirection and immune modulation strategies.

Our first clinical candidate, LEAD-452 is a first-in-class humanized bispecific tumor-targeting 4-1BB agonist trimerbody with a differential trimeric configuration compared to other 4-1BB agonist antibodies currently in development. LEAD-452 has been shown to induce potent anti-tumor activity without systemic cytokine production and liver toxicity. LEAD-452 is about to enter clinical trials as a monotherapy and in combination with checkpoint inhibitors by Trimerbody Pharma and external collaborators.

Trimerbody Pharma has developed a comprehensive preclinical package that differentiates LEAD-452 from other bispecific tumor-specific 4-1BB agonistic antibodies. We are launching our new name at an important inflection point in the development of our portfolio as we work to expand our initial findings into indications where we believe it has the potential to benefit many more patients.